Therapeutics News and Research

RSS

Mount Sinai Health System launches new Alopecia Areata Center of Excellence

In an unparalleled effort to deliver outstanding comprehensive care and to employ revolutionary approaches to novel therapeutics around the skin condition alopecia areata, the Mount Sinai Health System has launched the Alopecia Areata Center of Excellence.

21 Mar 2022

LJI study may open the door to new Parkinson's treatments and diagnostics

Scientists at La Jolla Institute for Immunology have found that people with Parkinson's disease have a clear "genetic signature" of the disease in their memory T cells.

21 Mar 2022

Study explores novel antiviral activity of PAD inhibitors against human beta-coronaviruses HCoV-OC43 and SARS-CoV-2

In a new study, researchers aimed to determine if peptidyl-arginine deiminases inhibitors may be used as a novel class of host-targeting antivirals against human coronaviruses.

21 Mar 2022

Glycogen synthase kinase-3 inhibitors found to attenuate COVID-19-associated cytokine storm

In a new study, researchers investigated whether the SARS-CoV-2 spike protein and its S2 subunit induced the expression of C–X–C motif chemokine 10, a subset of cytokine.

21 Mar 2022

Study aimed to identify the direct pathway that associates integrins with vascular dysregulation during SARS-CoV-2 infection

Researchers demonstrated the role of integrin signaling in vascular dysfunction associated with SARS-CoV-2 infection.

21 Mar 2022

Pfizer CEO pushes yearly shots for covid. Not so fast, experts say.

When Pfizer CEO Albert Bourla said March 13 that all Americans would need a second booster shot, it struck many covid experts as a self-serving remark without scientific merit. It also set off spasms of doubt over the country's objectives in its fight against the coronavirus.

21 Mar 2022

Sex-specific differences in T-cell responses to COVID-19

Researchers evaluate both neutralizing activity and T-cell responses in SARS-CoV-2 infected individuals with mild symptoms linked to a single spreading event.

20 Mar 2022

How does the non-structural protein 1 affect COVID-19 pathogenicity?

Researchers discuss the effects of the SARS-CoV-2 non-structural protein 1 (Nsp1), which binds to the ribosomal subunit thus inhibiting translation.

20 Mar 2022

Cov2clusters: Novel method for producing stable genomic clusters of SARS-CoV-2 cases

Researchers present a novel method for producing stable genomic clustering of SARS-CoV-2 cases, Cov2clusters.

20 Mar 2022

UT Dallas researchers explore origins of chronic pain and the potential for better treatments

An investigation into how human nerve cells differ from animal cells has provided researchers from The University of Texas at Dallas' Center for Advanced Pain Studies with important clues in the pursuit of more effective treatments for chronic pain.

19 Mar 2022

Study: Targeting astrocytes reduces tau-related brain damage and inflammation in mice

Alzheimer's disease is the most common and best known of the tauopathies, a set of neurodegenerative brain diseases caused by toxic tangles of the protein tau.

18 Mar 2022

Texas Biomed and UAB partnership uncovers a new, potent antibody cocktail against all coronaviruses

As SARS-CoV-2 has continued to evolve and outsmart existing treatments, scientists have not let up looking for ever-more effective tools to keep people safe and successfully recover from COVID-19, and to prepare for future outbreaks.

18 Mar 2022

Covalent protein nanobodies for neutralizing SARS-CoV-2 and its variants

Researchers developed covalent nanobodies to neutralize severe acute respiratory syndrome coronavirus-2 and its variants.

18 Mar 2022

Why does the SARS-CoV-2 Omicron variant escape immunity?

Researchers reveal the underlying mechanism associated with the Omicron variant’s increased transmissibility and ability to evade immunity.

17 Mar 2022

It was already hard to find Evusheld, a covid prevention therapy. Now it’s even harder.

As immunocompromised people across the country work to get Evusheld, a potentially lifesaving covid therapy, several hundred providers of the injections were removed from a federal dataset on Wednesday night, making the therapy even harder to locate.

17 Mar 2022

MHRA authorizes new medicine for COVID-19 prevention

A new medicine, Evusheld (tixagevimab/cilgavimab), has today been authorised for COVID-19 prevention by the Medicines and Healthcare products Regulatory Agency (MHRA) after meeting the UK regulatory standards of safety, quality and effectiveness.

17 Mar 2022

Novel fusion inhibitor blocks SARS-CoV-2 spike-mediated cell-cell fusion

Researchers constructed a novel fusion inhibitor−based recombinant protein, referred to as 5−Helix, to block SARS-CoV-2 spike-mediated cell-cell fusion.

17 Mar 2022

Transcription factors work together to drive cancer cell proliferation

Scientists have discovered that a well-established cancer cell transcription factor and its newly identified co-factor work together to drive cancer cell proliferation, according to findings published in Science Advances.

16 Mar 2022

Study finds a promising new target for immunity-boosting cancer treatments

Tumors can use an enzyme called ART1 to thwart antitumor immune cells, making the enzyme a promising new target for immunity-boosting cancer treatments, according to a study from researchers at Weill Cornell Medicine and Albert Einstein College of Medicine.

16 Mar 2022

New insight into how gut bacteria work to counter intestinal inflammation

Bile acids made by the liver have long been known for their critical role in helping to absorb the food we ingest.

16 Mar 2022

Therapeutics News and Research

Mount Sinai Health System launches new Alopecia Areata Center of Excellence

LJI study may open the door to new Parkinson's treatments and diagnostics

Study explores novel antiviral activity of PAD inhibitors against human beta-coronaviruses HCoV-OC43 and SARS-CoV-2

Glycogen synthase kinase-3 inhibitors found to attenuate COVID-19-associated cytokine storm

Study aimed to identify the direct pathway that associates integrins with vascular dysregulation during SARS-CoV-2 infection

Pfizer CEO pushes yearly shots for covid. Not so fast, experts say.

Sex-specific differences in T-cell responses to COVID-19

How does the non-structural protein 1 affect COVID-19 pathogenicity?

Cov2clusters: Novel method for producing stable genomic clusters of SARS-CoV-2 cases

UT Dallas researchers explore origins of chronic pain and the potential for better treatments

Study: Targeting astrocytes reduces tau-related brain damage and inflammation in mice

Texas Biomed and UAB partnership uncovers a new, potent antibody cocktail against all coronaviruses

Covalent protein nanobodies for neutralizing SARS-CoV-2 and its variants

Why does the SARS-CoV-2 Omicron variant escape immunity?

It was already hard to find Evusheld, a covid prevention therapy. Now it’s even harder.

MHRA authorizes new medicine for COVID-19 prevention

Novel fusion inhibitor blocks SARS-CoV-2 spike-mediated cell-cell fusion

Transcription factors work together to drive cancer cell proliferation

Study finds a promising new target for immunity-boosting cancer treatments

New insight into how gut bacteria work to counter intestinal inflammation

Understanding the DNA Damage Response in Innate Immunity eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News